3 Stocks Pulling The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 128 points (-0.8%) at 16,374 as of Friday, April 25, 2014, 1:00 PM ET. The NYSE advances/declines ratio sits at 926 issues advancing vs. 2,054 declining with 148 unchanged.

The Drugs industry currently sits down 2.3% versus the S&P 500, which is down 0.7%. On the negative front, top decliners within the industry include Cytokinetics ( CYTK), down 61.9%, Regeneron Pharmaceuticals ( REGN), down 2.6%, Actavis ( ACT), down 2.0%, Teva Pharmaceutical Industries ( TEVA), down 1.8% and Alexion Pharmaceuticals ( ALXN), down 1.2%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Intercept Pharmaceuticals ( ICPT) is one of the companies pushing the Drugs industry lower today. As of noon trading, Intercept Pharmaceuticals is down $12.44 (-4.6%) to $259.11 on light volume. Thus far, 174,363 shares of Intercept Pharmaceuticals exchanged hands as compared to its average daily volume of 603,300 shares. The stock has ranged in price between $256.13-$267.87 after having opened the day at $267.04 as compared to the previous trading day's close of $271.56.

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. Intercept Pharmaceuticals has a market cap of $5.1 billion and is part of the health care sector. Shares are up 297.7% year-to-date as of the close of trading on Thursday. Currently there are 4 analysts that rate Intercept Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Intercept Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow. Get the full Intercept Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Forest Laboratories ( FRX) is down $1.40 (-1.5%) to $90.05 on light volume. Thus far, 997,916 shares of Forest Laboratories exchanged hands as compared to its average daily volume of 3.8 million shares. The stock has ranged in price between $89.96-$91.47 after having opened the day at $91.16 as compared to the previous trading day's close of $91.45.

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe. Forest Laboratories has a market cap of $24.8 billion and is part of the health care sector. Shares are up 52.3% year-to-date as of the close of trading on Thursday. Currently there are 7 analysts that rate Forest Laboratories a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Forest Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, good cash flow from operations and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Forest Laboratories Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Illumina ( ILMN) is down $9.75 (-6.4%) to $141.93 on average volume. Thus far, 1.3 million shares of Illumina exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $141.00-$150.64 after having opened the day at $148.22 as compared to the previous trading day's close of $151.68.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $19.7 billion and is part of the health care sector. Shares are up 37.2% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Illumina Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers